Dendritic cell activation and MHC class II–dependent antigen presentation

Dendritic cell (DC) activation and MHC class II–dependent antigen presentation is a multi-step biological process essential for the initiation of adaptive immunity (StatPearls, 2023). This pathway involves the maturation of DCs upon sensing pathogens via pattern recognition receptors, which triggers the upregulation of MHC class II molecules and co-stimulatory proteins such as CD80 and CD86 (PubMed, PMID: 30214036). Exogenous antigens are internalized and degraded into peptides within endolysosomal compartments, where they are loaded onto MHC II molecules with the assistance of the chaperone HLA-DM (UniProt, P06340). This process is formally categorized in biological databases as a complex series of events including antigen uptake, processing, and the transport of MHC-peptide complexes to the cell surface (Reactome, R-HSA-2132295). This pathway is a critical therapeutic target; for instance, TLR agonists like Imiquimod are used to stimulate DC activation in viral infections and skin cancers, while co-stimulation blockers like Abatacept inhibit the downstream effects of this presentation in rheumatoid arthritis (NCBI, NBK541064). Dysregulation of this process is implicated in various conditions, including autoimmune diseases, where it leads to the loss of self-tolerance, and oncology, where tumor-induced suppression of DC maturation facilitates immune evasion (PubMed, PMID: 31110354). Modern immunotherapies, such as dendritic cell vaccines, seek to harness this pathway to direct the immune system against specific tumor-associated antigens (PubMed, PMID: 28438787).

Other names

Dendritic cell maturationMHC class II antigen processing and presentationExogenous pathway of antigen presentationDC activation

Modulation of Toll-like receptor signaling to induce maturation, blockade of co-stimulatory molecule interactions (e.g., CD80/86 with CD28), or suppression of MHC class II expression and endosomal processing.